Skip to main content
    C

    Citius Pharmaceuticals Inc (CTXR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.53
    -0.01 (-1.40%)

    Market Cap: $14.69M

    Last updated: Nov 17, 2026 at 11:00 AM ET

    Citius Pharmaceuticals Inc (CTXR) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Citius Pharmaceuticals are Cyclerion Therapeutics (CYCN), Context Therapeutics (CNTX) and Cocrystal Pharma (COCP). By market cap, Citius Pharmaceuticals ranks 9th of the 13 companies on this page; NextCure (NXTC) is the largest at $29.31M.

    Peer Comparison

    CTXR's ROIC of -84.3% is above the peer median of -650.8%, and its revenue growth of 0.0% is above the median of -1.4%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Citius Pharmaceuticals (CTXR)$14.69MN/A1.9x0.0%-84.3%0.0%0.00%
    Cyclerion Therapeutics Inc (CYCN)$15.73MN/AN/A0.0%N/A-43.2%0.00%
    Context Therapeutics Inc (CNTX)$16.61MN/AN/A0.0%N/A0.0%0.00%
    Cocrystal Pharma Inc (COCP)$18.88MN/A39.2x0.0%N/A26.9%0.00%
    Plus Therapeutics Inc (PSTV)$26.64MN/A2.0x-230.2%-827.8%-2.9%0.00%
    Biocardia Inc (BCDA)$12.58MN/AN/A0.0%N/A-100.0%0.00%
    Intensity Therapeutics, Inc. Common stock (INTS)$10.17MN/AN/A0.0%N/A0.0%0.00%
    Passage Bio Inc (PASG)$13.68MN/AN/A0.0%N/A0.0%0.00%
    Tvardi Therapeutics, Inc. (TVRD)$15.74MN/AN/A0.0%N/A0.0%0.00%
    Lite Strategy, Inc. (LITS)$25.30MN/AN/A0.0%N/A0.0%0.00%
    NextCure Inc (NXTC)$29.31MN/AN/A0.0%N/A-100.0%0.00%
    CytoMed Therapeutics Limited Ordinary Shares (GDTC)$9.90MN/A16.4x0.0%-72.3%-15.9%0.00%
    Pluri Inc. (PLUR)$15.09MN/A8.7x0.0%-650.8%-15.8%0.00%
    Peer median$15.73MN/A12.6x0.0%-650.8%-1.4%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Citius Pharmaceuticals, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Cyclerion Therapeutics Inc (CYCN)
    Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery, development...
    Context Therapeutics Inc (CNTX)
    Centrexion Therapeutics Corporation, a late-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel, non-opioid...
    CNTX competitors
    Cocrystal Pharma Inc (COCP)
    Cocrystal Pharma, Inc., a biotechnology company, is focused on the discovery and development of antiviral therapeutic treatments for serious and / or chronic...
    COCP competitors
    Plus Therapeutics Inc (PSTV)
    Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacturing...
    PSTV competitors
    Biocardia Inc (BCDA)
    BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapies for cardiovascular disease.
    BCDA competitors
    Intensity Therapeutics, Inc. Common stock (INTS)
    Intensity Therapeutics, Inc. is a pioneering biotechnology firm committed to revolutionizing cancer treatment through cutting-edge drug delivery systems.
    INTS competitors
    Passage Bio Inc (PASG)
    Passage Bio, Inc., a genetic drug company, develops transformative therapies for rare monogenic central nervous system (CNS) diseases.
    PASG competitors
    Tvardi Therapeutics, Inc. (TVRD)
    Tvardi Therapeutics, Inc. is an innovative clinical-stage biopharmaceutical company focused on developing novel oncology therapies to meet critical unmet...
    TVRD competitors
    Lite Strategy, Inc. (LITS)
    Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer.
    LITS competitors
    NextCure Inc (NXTC)
    NextCure, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of novel immunomedicines to treat cancer and other...
    NXTC competitors
    CytoMed Therapeutics Limited Ordinary Shares (GDTC)
    CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human...
    Pluri Inc. (PLUR)
    Pluri Inc. is an innovative biotechnology company at the forefront of regenerative medicine and immunotherapy...
    PLUR competitors

    Frequently Asked Questions About CTXR

    Who are Citius Pharmaceuticals' main competitors?

    The companies most similar to Citius Pharmaceuticals include Cyclerion Therapeutics (CYCN), Context Therapeutics (CNTX), Cocrystal Pharma (COCP), Plus Therapeutics (PSTV) and Biocardia (BCDA), listed from the closest match.

    Who is Citius Pharmaceuticals' biggest competitor?

    NextCure (NXTC) is the largest of the similar companies at $29.31M; Cyclerion Therapeutics (CYCN) is the closest match by business profile, size, sector and industry.

    How does CTXR stock compare with its competitors?

    CTXR's P/S is 1.9x against a peer median of 12.6x; its net margin is 0.0% against a peer median of 0.0%.

    Which of Citius Pharmaceuticals' competitors pays a higher dividend?

    Citius Pharmaceuticals pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Citius Pharmaceuticals bigger than its competitors?

    No. Citius Pharmaceuticals is 9th by market cap among the 13 companies on this page; the largest is NextCure (NXTC) at $29.31M.